By Fineline Cube 
China-based biotech Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) announced its financial results for the second quarter of 2025 on August 7, 2025. Net product revenue reached $109.1 million, marking a 10% year-over-year increase at constant exchange rates. This growth was primarily driven by increased sales of Vyvgart, Sulbactam-Durlobactam, and Nuzyra, partially offset by a slowdown in Zejula sales.
Key Product Sales Performance
- Vyvgart and Vyvgart Hytrulo (Efgartigimod alfa injection and subcutaneous injection): Net product revenue increased by 46% quarter-over-quarter to $26.5 million in Q2 2025, from $18.1 million in Q1 2025. This growth was attributed to longer treatment duration and enhanced market penetration.
- Zejula (Niraparib): Net product revenue was $41.0 million in Q2 2025, compared to $45.0 million in the same period in 2024. The sales slowdown was due to changes in the competitive landscape for PARPi products.
- Sulbactam-Durlobactam: Launched in Q4 2024, net product revenue was $4.6 million in Q2 2025.
- Nuzyra (Omadacycline): Net product revenue was $14.3 million in Q2 2025, up from $12.3 million in the same period in 2024. This growth was due to expanded market coverage and increased penetration.
Near-Term NMPA Filings
- Bemarituzumab (FGFR2b): Planned submission of a Biologics License Application (BLA) for first-line gastric cancer in the second half of 2025.
- Tumor Treating Fields (TTFields): Planned submission of a marketing authorization application for first-line pancreatic cancer in the second half of 2025.
- Efgartigimod (FcRn): Planned submission of marketing authorization applications for the pre-filled syringe formulation of efgartigimod for both generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) in the second half of 2025.
Near-Term NMPA Approvals
- Xanomeline-Trospium (KarXT): For schizophrenia.
- Tisotumab Vedotin (TIVDAK): For recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
- Repotrectinib: For NTRK-positive solid tumors.
Revenue Guidance
For the full year 2025, the company’s revenue guidance is set between $560 million and $590 million.-Fineline Info & Tech